Tempus AI TEM is currently in its 10th year of business and on track to hit a long-anticipated milestone. In its first-quarter 2025 earnings report, the AI-driven healthcare company guided full-year ...

Tempus AI delivered strong Q1 results, driven by the Ambry Genetics acquisition and a major AstraZeneca contract, boosting ...

Aliso Viejo-based Ambry Genetics Corp. on Nov. 4 announced an agreement to be acquired for $600 million by Tempus AI Inc. “They’ve achieved one of the rare things in our space where you actually have ...

Financing was provided by Ares Management Credit funds. Ambry Genetics will continue operations as a wholly-owned subsidiary of Tempus under its current leadership team. This press release ...

Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. Tempus AI announced today it is acquiring genetic ...

Tempus AI, Inc. is revolutionizing healthcare genomics with AI and data partnerships. Click here to read an analysis on TEM stock now.

Third Quarter 2024 Financial Results Additional Operating Highlights Ambry Genetics Acquisition Tempus today announced that it has entered into an agreement to acquire Ambry Genetics, a leader in ...